查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1375968

肝癌治療藥物市場規模、佔有率和趨勢分析報告：2023-2030 年按藥物類別、地區和細分市場分類的趨勢

Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug Class (Targeted Therapy, Immunotherapy, Chemotherapy), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 92 Pages | 商品交期: 2-10個工作天內

價格

肝癌治療藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球肝癌藥物市場規模預計將達到78.3億美元，預測期內年複合成長率為15.3%。

肝癌市場的成長很大程度上取決於新藥的可得性、強大的產品線的存在以及公眾意識的提高等因素。肝癌患者數量的增加是由於不健康的生活習慣和老年人口的增加所造成的。這有利於肝癌藥物市場。針對不能耐受多吉美患者的二線治療的開發預計將對肝癌領域產生重大影響。

肝癌是全球第五大常見癌症，佔癌症死亡人數的 9.0%。 2012年，新診斷肝癌782,451人，肝癌死亡745,533人。由於其極具侵襲性和低存活率，原發性肝癌仍是一個重要的公共衛生問題。肝細胞癌佔原發性肝癌的大部分（75-90%）。肝癌的許多顯著原因，包括肝炎感染和肝硬化，都是可以改變的，改變生活方式和接種肝炎疫苗等預防策略為降低肝癌的發病率和死亡率提供了良好的前景。

肝癌治療藥物市場報告亮點

  • 2022年，北美將佔市佔率超過43.20%。多種產品的推出、新療法的採用增加以及龐大的目標人口正在促進該地區的市場成長。
  • 近期多個新藥的核准是擴大肝癌治療市場的關鍵因素之一。免疫腫瘤學領域的新產品和聯合治療預計將在未來年度改變遊戲規則。
  • 特別是，包括檢查點抑制劑在內的聯合治療將被引入一線治療中，以滿足關鍵的未滿足需求，例如克服腫瘤抗藥性、提高無惡化生存期和維持生活品質。
  • 肝癌市場管道具有高度創新性和多樣性。大量未滿足的需求為開發創新的一流治療方法提供了絕佳的機會。近年來，溶瘤病毒和RNA干擾（RNAi）技術等創新治療方法在市場上獲得了巨大的關注。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 普及和成長前景圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 肝癌治療藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 治療藥物市場：藥物類別的估計與趨勢分析

  • 肝癌藥物市場：要點
  • 肝癌藥物市場：2022 年和 2030 年藥物類別趨勢和市場佔有率分析
  • 標靶治療
  • 免疫療法
  • 化療

第5章 治療藥物市場：區域估計與趨勢分析

  • 區域展望
  • 按地區分類的肝癌藥物市場：要點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第6章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • Exelixis, Inc.
    • Merck KGaA
Product Code: GVR-2-68038-513-7

Liver Cancer Drug Market Growth & Trends:

The global liver cancer drug market size is expected to reach USD 7.83 billion by 2030, registering a CAGR of 15.3% during the forecast period, according to a new report by Grand View Research, Inc.. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75-90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights:

  • The North America accounted for more than 43.20% of the market in 2022. Multiple product launches, increasing adoption of novel therapeutics, and presence of a large target population are contributing to the growth of the market in the region
  • Approval of multiple novel drugs in recent years is one of the key factors augmenting the liver cancer treatment market. New immuno-oncology products and combination therapies are anticipated to change the landscape over the next years.
  • Combination regimens, specifically those including checkpoint inhibitors, will be introduced in the first-line setting to target major unmet needs, including overcoming tumour resistance, improving progression free survival, and maintaining quality of life
  • The liver cancer market pipeline is highly innovative and diverse. The market offers tremendous opportunities to develop breakthrough first-in-class therapies due to high unmet needs. In recent years, innovative treatment approaches such as oncolytic viruses or RNA interference (RNAi) technology have gained significant traction in the market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Class
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Liver Cancer Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Liver Cancer Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Liver Cancer Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Liver Cancer Drugs Market: Key Takeaways
  • 4.2. Liver Cancer Drugs Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Targeted Therapy
    • 4.3.1. Targeted therapy market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.4. Immunotherapy
    • 4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.5. Chemotherapy
    • 4.5.1. Chemotherapy market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 5. Liver Cancer Drugs Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Outlook
  • 5.2. Liver Cancer Drugs Market by Region: Key Takeaways
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Denmark
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Norway
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. South Africa
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. Bayer AG
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Bristol-Myers Squibb Company
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Eisai Co., Ltd.
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Exelixis, Inc.
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Merck KGaA
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 North America liver cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4 U.S. liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Canada liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 Europe liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 Europe liver cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 8 Germany liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 UK liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 France liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 11 Italy liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 Spain liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Denmark liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Sweden liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 Norway liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific liver cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 18 China liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 Japan liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 India liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Australia liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Thailand liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 South Korea liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 24 Latin America liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Latin America liver cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 26 Brazil liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Mexico liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 28 Argentina liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa liver cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 South Africa liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 UAE liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Kuwait liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Liver cancer drugs: Market outlook
  • Fig. 8 Liver cancer drugs: Competitive insights
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Liver cancer drugs market driver impact
  • Fig. 13 Liver cancer drugs market restraint impact
  • Fig. 14 Liver cancer drugs market strategic initiatives analysis
  • Fig. 15 Liver cancer drugs market: Drug class movement analysis
  • Fig. 16 Liver cancer drugs market: Drug class outlook and key takeaways
  • Fig. 17 Targeted therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Immunotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Global liver cancer drugs market: Regional movement analysis
  • Fig. 21 Global liver cancer drugs market: Regional outlook and key takeaways
  • Fig. 22 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)